Trending

Diabetes

Health Innovators: Senseonics’ Francine Kaufman

Health Innovators: Senseonics’ Francine Kaufman

In the most recent of the Health Innovators video series, pharmaphorum’s founder, Dr Paul Tunnah, chats with the

X

Health Innovators: Senseonics’ Francine Kaufman

https://pharmaphorum.com/digital/health-innovators-senseonics-francine-kaufman/

Novo Nordisk CEO reassures UK patients over Brexit insulin supplies

Novo Nordisk CEO reassures UK patients over Brexit insulin supplies

Novo Nordisk has doubled its insulin stockpile in the UK, amid patients’ fears that a no-deal Brexit could

X

Novo Nordisk CEO reassures UK patients over Brexit insulin supplies

https://pharmaphorum.com/news/novo-nordisk-doubles-uk-insulin-stockpile-in-case-of-no-deal-brexit/

AstraZeneca improves diabetes pen to maintain its market share

The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug

X

AstraZeneca improves diabetes pen to maintain its market share

https://pharmaphorum.com/news/astrazeneca-improves-diabetes-pen-to-maintain-its-market-share/

FDA warns of genital gangrene risk with diabetes drug class

The US regulator released an official risk warning of a rare genital infection identified in 12 patients, including

X

FDA warns of genital gangrene risk with diabetes drug class

https://pharmaphorum.com/news/risk-sglt2-inhibitors-fda-warns/

Type 2 diabetes research: fewer side effects from modified medication

Type 2 diabetes research: fewer side effects from modified medication

Scientists have made progress in the quest to find medication for Type 2 diabetes that causes fewer side

X

Type 2 diabetes research: fewer side effects from modified medication

https://pharmaphorum.com/news/diabetes-research-modified-medication/

Real-world diabetes study CONFIRMs positive comparative efficacy for Novo’s Tresiba

Real-world diabetes study CONFIRMs positive comparative efficacy for Novo’s Tresiba

Novo Nordisk presented the latest results for its diabetes injectable Tresiba last weekend. These demonstrated significantly better control

X

Real-world diabetes study CONFIRMs positive comparative efficacy for Novo’s Tresiba

https://pharmaphorum.com/news/tresiba-improved-sugar-control-decreased-hypos/

Novo’s diabetes pill beats injections in head-to-head trials

Novo’s diabetes pill beats injections in head-to-head trials

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight

X

Novo’s diabetes pill beats injections in head-to-head trials

https://pharmaphorum.com/news/novo-nordisks-success-with-oral-diabetes-drug/

J&J seals $2.1bn deal on sale of major diabetes devices firm

J&J seals $2.1bn deal on sale of major diabetes devices firm

As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson &

X

J&J seals $2.1bn deal on sale of major diabetes devices firm

https://pharmaphorum.com/news/jj-deal-glucose-monitoring-system/

Novo Nordisk undeterred after losing out on Ablynx takeover

Novo Nordisk undeterred after losing out on Ablynx takeover

After losing out to Sanofi in its pursuit of Belgian biotech Ablynx earlier this week, Novo Nordisk has put a brave face on the disappointment.

X

Novo Nordisk undeterred after losing out on Ablynx takeover

https://pharmaphorum.com/news/novo-nordisk-undeterred-losing-ablynx-takeover/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com